Dopaminergic treatment in idiopathic restless legs syndrome

Effects on subjective sleepiness

Ulf Kallweit, Ramin Khatami, Fabio Pizza, Johannes Mathis, Claudio L. Bassetti

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives: To assess frequency and characteristics of excessive daytime sleepiness (EDS) in restless legs syndrome (RLS) and the evolution of EDS under different RLS therapies. Methods: We analyzed data from the "Swiss RLS" study, which was conducted to compare treatment efficacy and safety of the dopamine agonist pramipexole (PPX) versus l-dopa/benserazide (L/B) in de novo patients with idiopathic RLS and performed as a randomized, double-dummy, comparative crossover trial. Primary outcome measure of the present study was the change in subjective sleepiness (as measured by Epworth sleepiness scale [ESS] score). There were 37 patients (21 women) included. Mean age was 56.6 years (range, 25-85 years), and mean body mass index was 24.6 (SD, ±3.5). Results: At baseline, EDS (as determined by an ESS score of >10) was found in 32% of the patients. Sleepy RLS patients were younger (P <0.001) than nonsleepy patients. Pramipexole and L/B both were effective in the treatment of RLS symptoms (IRLS score, P <0.001 and P = 0.002). Overall, ESS was reduced (main effect for "time", P = 0.02) independent from the dopaminergic substance. In 5 of 37 patients, ESS score deteriorated to greater than 10 under treatment (PPX = 3 patients, L/B = 2 patients). No sleep attack occurred. Conclusions: Excessive daytime sleepiness is frequent in RLS patients. Dopaminergic treatment usually promotes wakefulness, but infrequently leads to daytime sleepiness.

Original languageEnglish
Pages (from-to)276-278
Number of pages3
JournalClinical Neuropharmacology
Volume33
Issue number6
DOIs
Publication statusPublished - Nov 2010

Fingerprint

Restless Legs Syndrome
Benserazide
Dihydroxyphenylalanine
Therapeutics
Wakefulness
Dopamine Agonists
Cross-Over Studies
Sleep
Body Mass Index
Outcome Assessment (Health Care)
Safety

Keywords

  • Epworth sleepiness scale
  • excessive daytime sleepiness
  • L-dopa
  • pramipexole
  • restless legs syndrome

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Clinical Neurology

Cite this

Dopaminergic treatment in idiopathic restless legs syndrome : Effects on subjective sleepiness. / Kallweit, Ulf; Khatami, Ramin; Pizza, Fabio; Mathis, Johannes; Bassetti, Claudio L.

In: Clinical Neuropharmacology, Vol. 33, No. 6, 11.2010, p. 276-278.

Research output: Contribution to journalArticle

Kallweit, Ulf ; Khatami, Ramin ; Pizza, Fabio ; Mathis, Johannes ; Bassetti, Claudio L. / Dopaminergic treatment in idiopathic restless legs syndrome : Effects on subjective sleepiness. In: Clinical Neuropharmacology. 2010 ; Vol. 33, No. 6. pp. 276-278.
@article{82d3874bf7ae4d3a9e6ea603cd647748,
title = "Dopaminergic treatment in idiopathic restless legs syndrome: Effects on subjective sleepiness",
abstract = "Objectives: To assess frequency and characteristics of excessive daytime sleepiness (EDS) in restless legs syndrome (RLS) and the evolution of EDS under different RLS therapies. Methods: We analyzed data from the {"}Swiss RLS{"} study, which was conducted to compare treatment efficacy and safety of the dopamine agonist pramipexole (PPX) versus l-dopa/benserazide (L/B) in de novo patients with idiopathic RLS and performed as a randomized, double-dummy, comparative crossover trial. Primary outcome measure of the present study was the change in subjective sleepiness (as measured by Epworth sleepiness scale [ESS] score). There were 37 patients (21 women) included. Mean age was 56.6 years (range, 25-85 years), and mean body mass index was 24.6 (SD, ±3.5). Results: At baseline, EDS (as determined by an ESS score of >10) was found in 32{\%} of the patients. Sleepy RLS patients were younger (P <0.001) than nonsleepy patients. Pramipexole and L/B both were effective in the treatment of RLS symptoms (IRLS score, P <0.001 and P = 0.002). Overall, ESS was reduced (main effect for {"}time{"}, P = 0.02) independent from the dopaminergic substance. In 5 of 37 patients, ESS score deteriorated to greater than 10 under treatment (PPX = 3 patients, L/B = 2 patients). No sleep attack occurred. Conclusions: Excessive daytime sleepiness is frequent in RLS patients. Dopaminergic treatment usually promotes wakefulness, but infrequently leads to daytime sleepiness.",
keywords = "Epworth sleepiness scale, excessive daytime sleepiness, L-dopa, pramipexole, restless legs syndrome",
author = "Ulf Kallweit and Ramin Khatami and Fabio Pizza and Johannes Mathis and Bassetti, {Claudio L.}",
year = "2010",
month = "11",
doi = "10.1097/WNF.0b013e3181fd82a1",
language = "English",
volume = "33",
pages = "276--278",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Dopaminergic treatment in idiopathic restless legs syndrome

T2 - Effects on subjective sleepiness

AU - Kallweit, Ulf

AU - Khatami, Ramin

AU - Pizza, Fabio

AU - Mathis, Johannes

AU - Bassetti, Claudio L.

PY - 2010/11

Y1 - 2010/11

N2 - Objectives: To assess frequency and characteristics of excessive daytime sleepiness (EDS) in restless legs syndrome (RLS) and the evolution of EDS under different RLS therapies. Methods: We analyzed data from the "Swiss RLS" study, which was conducted to compare treatment efficacy and safety of the dopamine agonist pramipexole (PPX) versus l-dopa/benserazide (L/B) in de novo patients with idiopathic RLS and performed as a randomized, double-dummy, comparative crossover trial. Primary outcome measure of the present study was the change in subjective sleepiness (as measured by Epworth sleepiness scale [ESS] score). There were 37 patients (21 women) included. Mean age was 56.6 years (range, 25-85 years), and mean body mass index was 24.6 (SD, ±3.5). Results: At baseline, EDS (as determined by an ESS score of >10) was found in 32% of the patients. Sleepy RLS patients were younger (P <0.001) than nonsleepy patients. Pramipexole and L/B both were effective in the treatment of RLS symptoms (IRLS score, P <0.001 and P = 0.002). Overall, ESS was reduced (main effect for "time", P = 0.02) independent from the dopaminergic substance. In 5 of 37 patients, ESS score deteriorated to greater than 10 under treatment (PPX = 3 patients, L/B = 2 patients). No sleep attack occurred. Conclusions: Excessive daytime sleepiness is frequent in RLS patients. Dopaminergic treatment usually promotes wakefulness, but infrequently leads to daytime sleepiness.

AB - Objectives: To assess frequency and characteristics of excessive daytime sleepiness (EDS) in restless legs syndrome (RLS) and the evolution of EDS under different RLS therapies. Methods: We analyzed data from the "Swiss RLS" study, which was conducted to compare treatment efficacy and safety of the dopamine agonist pramipexole (PPX) versus l-dopa/benserazide (L/B) in de novo patients with idiopathic RLS and performed as a randomized, double-dummy, comparative crossover trial. Primary outcome measure of the present study was the change in subjective sleepiness (as measured by Epworth sleepiness scale [ESS] score). There were 37 patients (21 women) included. Mean age was 56.6 years (range, 25-85 years), and mean body mass index was 24.6 (SD, ±3.5). Results: At baseline, EDS (as determined by an ESS score of >10) was found in 32% of the patients. Sleepy RLS patients were younger (P <0.001) than nonsleepy patients. Pramipexole and L/B both were effective in the treatment of RLS symptoms (IRLS score, P <0.001 and P = 0.002). Overall, ESS was reduced (main effect for "time", P = 0.02) independent from the dopaminergic substance. In 5 of 37 patients, ESS score deteriorated to greater than 10 under treatment (PPX = 3 patients, L/B = 2 patients). No sleep attack occurred. Conclusions: Excessive daytime sleepiness is frequent in RLS patients. Dopaminergic treatment usually promotes wakefulness, but infrequently leads to daytime sleepiness.

KW - Epworth sleepiness scale

KW - excessive daytime sleepiness

KW - L-dopa

KW - pramipexole

KW - restless legs syndrome

UR - http://www.scopus.com/inward/record.url?scp=78650270941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650270941&partnerID=8YFLogxK

U2 - 10.1097/WNF.0b013e3181fd82a1

DO - 10.1097/WNF.0b013e3181fd82a1

M3 - Article

VL - 33

SP - 276

EP - 278

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 6

ER -